Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | CPT1A | P50416 | 12/20 | 0.62 |
| ▸ | CPT2 | P23786 | 11/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3148212 | 1.00 | ALDH1A1 (0.63) | ALDH1A1SMN1; SMN2CPT1ACPT2KMT2A | |
| SCHEMBL11424895 | 0.96 | CPT1A (0.67) | ALDH1A1SMN1; SMN2CPT1ACPT2CPT1B | |
| SCHEMBL3187180 | 0.94 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2CPT1ACPT2KMT2A | |
| SCHEMBL3187156 | 0.94 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2CPT1ACPT2KMT2A | |
| SCHEMBL6794547 | 0.92 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2CPT1ACPT2KMT2A | |
| SCHEMBL6794537 | 0.92 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2CPT1ACPT2KMT2A | |
| SCHEMBL11481661 | 0.89 | CPT1A (0.60) | CPT1ACPT2KMT2AMEN1KDM4E | |
| SCHEMBL14948377 | 0.89 | CPT1A (0.60) | ALDH1A1SMN1; SMN2CPT1ACPT2KMT2A | |
| SCHEMBL7167933 | 0.89 | CPT1A (0.60) | CPT1ACPT2KMT2AMEN1KDM4E | |
| SCHEMBL6789622 | 0.89 | KMT2A (0.60) | ALDH1A1SMN1; SMN2CPT1ACPT2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6531612-B2 | Pyrrolidine-2-carboxylic acid cyano-methyl amide derivatives useful for treating diseases associated with cystein proteases, such as osteoporosis, osteoarthritis, rheumatoid arthritis, tumor metastasis, glomerulonephritis | HOFFMAN-LA ROCHE INC. | 2003-03-11 | — | — | US | claimed |
| US-20010008901-A1 | Nitrile derivatives that inhibit cathepsin K | F. HOFFMANN-LA ROCHE AG (CH) | 2001-07-19 | — | — | US | claimed |
| US-4085207-A | AND AT LEAST ONE OF N-ACYL-L-TRYPTOPHANS AND N-ACYL-L-PROLINES | OTSUKA PHARMACEUTICAL FACTORY, INC. (JA) | 1978-04-18 | — | — | US | claimed |
| EP-1244621-B1 | NITRILE DERIVATIVES AS CATHEPSIN K INHIBITORS | HOFFMANN LA ROCHE (CH) | 2006-09-13 | — | — | EP | disclosed |
| EP-1505062-A1 | Heterocyclic derivatives and their use as antithrombotic agents | Akzo Nobel N.V. (NL) | 2005-02-09 | — | — | EP | disclosed |
| US-6797710-B2 | CARDIOVASCULAR DISORDERS; SERINE PROTEASE INHIBITOR; ADMINISTERING BY MOUTH; BIOAVAILABILITY | AKZO NOBEL N.V. (NL) | 2004-09-28 | — | — | US | disclosed |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | MERCK SHARP & DOHME B.V. (NL) | 2003-07-10 | — | — | US | disclosed |
| US-6531612-B2 | Pyrrolidine-2-carboxylic acid cyano-methyl amide derivatives useful for treating diseases associated with cystein proteases, such as osteoporosis, osteoarthritis, rheumatoid arthritis, tumor metastasis, glomerulonephritis | HOFFMAN-LA ROCHE INC. | 2003-03-11 | — | — | US | disclosed |
| EP-1244621-A1 | NITRILE DERIVATIVES AS CATHEPSIN K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-02 | — | — | EP | disclosed |
| US-6444672-B1 | ORAL BIOVAILABILITY; INHIBITORS OF THROMBIN AND/OR FACTOR XA; SERINE PROTEASE INHIBITOR | AKZO NOBEL N.V. (NL) | 2002-09-03 | — | — | US | disclosed |
| US-6432955-B1 | ANTICOAGULANTS | AKZO NOBEL N.V. (NL) | 2002-08-13 | — | — | US | disclosed |
| WO-2001047886-A1 | NITRILE DERIVATIVES AS CATHEPSIN K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-07-05 | — | — | WO | disclosed |
| US-6194409-B1 | SERINE PROTEASE INHIBITOR; BIOAVAILABILITY WHEN ADMINISTERED BY MOUTH | AKZO NOBEL N.V. (NL) | 2001-02-27 | — | — | US | disclosed |
| EP-0975600-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | Akzo Nobel N.V. (NL) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998047876-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | AKZO NOBEL N.V. (NL) | 1998-10-29 | — | — | WO | disclosed |
| EP-0019411-B1 | 1-PHENYL-2-AMINOETHANOL DERIVATIVES, PROCESSES FOR THEIR MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS THEREOF | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-12-22 | — | — | EP | disclosed |
| US-4323575-A | TOPICAL ANTIINFLAMMATORY AGENTS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1982-04-06 | — | — | US | disclosed |
| EP-0019411-A1 | 1-Phenyl-2-aminoethanol derivatives, processes for their manufacture and pharmaceutical compositions thereof | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1980-11-26 | — | — | EP | disclosed |
| US-4217269-A | FOR SPECTROPHOTOMETRIC MEASUREMENT OF PROTEOLYTIC ENZYMES | ABBOTT LABORATORIES (US) | 1980-08-12 | — | — | US | disclosed |
| US-4085207-A | AND AT LEAST ONE OF N-ACYL-L-TRYPTOPHANS AND N-ACYL-L-PROLINES | OTSUKA PHARMACEUTICAL FACTORY, INC. (JA) | 1978-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010008901-A1 | Nitrile derivatives that inhibit cathepsin K | CTSK, CTSH, CTSS | ALDH1A1 2193/4885SMN1; SMN2 683/4885CPT1A 2363/4885 |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | F2, F12, VKORC1 | ALDH1A1 170/4885SMN1; SMN2 2799/4885CPT1A 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.